Company Overview and News

Amazon Roundup: Prime Day, Network Switches, PillPack, More

2018-07-16 zacks - 1
Amazon’s (AMZN - Free Report) big shopping day for Prime members, akin to Alibaba’s (BABA - Free Report) Single’s Day, is kicking off today. Other than that, this roundup covers its PillPack acquisition, foray into network switching, Go Store additions, Chile expansion and logistics rumors.

Can Cisco Put a Dent in Amazon’s Networking Plans

2018-07-16 investorplace
Shares of Cisco (NASDAQ:CSCO) declined 4% to close at $41.78, on July 13, following rumors that Amazon’s (NASDAQ:AMZN) Web Services platform (“AWS”) intends to market network switches to business customers. However, we believe the fears are overblown considering CSCO’s dominant market share, domain expertise and expanding clientele.

Cisco's Solid Portfolio to Thwart Amazon's Networking Plans

2018-07-16 zacks
Shares of Cisco (CSCO - Free Report) declined 4% to close at $41.78, on Jul 13, following rumors that Amazon Web Services (“AWS”) intends to market network switches to business customers. However, we believe the fears are overblown considering Cisco’s dominant market share, domain expertise and expanding clientele. Per a report, Amazon’s aggressive pricing strategy will not only position it well to foray into the market but also aid it in gaining competitive edge over the companies in the space, including Cisco, Arista Networks (ANET - Free Report) , Juniper (JNPR - Free Report) , among others.

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="